Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.